Giloy Drug Interactions Indian Doctors Don't Mention — Metformin, Warfarin, Thyroid & More (2026)

Sixty to seventy percent of Indians on chronic prescription medications who also take herbal supplements do not tell their treating doctor. Of the small fraction who do disclose, most are met with a shrug — “it’s natural, it should be fine.” Of the doctors who do flag concerns, most warn about ashwagandha (because of the well-publicised 35 global liver injury cases) and stop there.

Giloy carries the same caution category for interactions, and almost none of it is on product packaging, in pharmacist counselling, or in the typical clinical conversation.

This is the drug-by-drug guide that should be standard for any Indian on chronic medication considering Giloy. It is based on Giloy’s known pharmacology — immunostimulant action, hypoglycemic effect, antiplatelet activity, hepatic involvement — and on documented clinical interactions reported in Indian rheumatology, hepatology, endocrinology, and transplant medicine literature. It is not exhaustive, but it covers the medication classes most Indians on chronic prescriptions are actually taking.

How Giloy Causes Drug Interactions

Before the drug-by-drug breakdown, here are the four mechanisms through which Giloy interacts with other drugs. Understanding the mechanism makes individual interactions easier to anticipate.

Mechanism 1: Immunostimulation

Giloy contains tinosporin, cordifolioside A and B, magnoflorine, and other compounds that increase macrophage activity, NK cell counts, and pro-inflammatory cytokine production. This is the “immunity booster” effect that drove COVID-era marketing.

In healthy people, mild immune stimulation may be neutral or beneficial. In patients on immunosuppressants (transplant medications, autoimmune disease treatments, cancer immunotherapy), this stimulation directly opposes therapy. In patients with autoimmune disease, it can flare the disease.

Mechanism 2: Hypoglycemic Action

Giloy lowers blood glucose through berberine-mediated AMPK activation, increased peripheral glucose uptake, and mild insulin sensitisation. The effect is real but modest — typically 10–25 mg/dL fasting glucose reduction over 2–8 weeks.

In non-diabetics, this is generally inconsequential. In diabetics on glucose-lowering drugs, the additive effect can trigger hypoglycemia.

Mechanism 3: Antiplatelet Effect

Giloy has documented antiplatelet activity in Phytotherapy Research and other journals. The clinical effect is small in isolation but additive with anticoagulants and antiplatelets.

In healthy people not on blood thinners, the effect is sub-clinical. In patients on warfarin, clopidogrel, aspirin, or post-cardiac procedure anticoagulants, the combined antithrombotic effect can produce excessive bleeding.

Mechanism 4: Hepatic Co-Stress

Giloy has documented hepatotoxic potential — confirmed in the 2021 Mumbai hepatitis case series and subsequent Indian DILI reports. When combined with other hepatotoxic drugs, the cumulative load increases the likelihood of unmasking liver injury in genetically susceptible individuals.

Diabetes Medications: The Hypoglycemia Risk

The most clinically relevant interaction for Indian patients is between Giloy and diabetes medications.

Metformin

Metformin is the first-line drug for type 2 diabetes in India and is taken by tens of millions of Indians. Giloy adds to its glucose-lowering effect.

The combined effect typically produces:

• An additional 10–20 mg/dL drop in fasting glucose beyond metformin alone
• Occasional symptomatic hypoglycemia in patients on stable metformin doses
• Improved HbA1c by 0.3–0.5% in patients adding Giloy to existing metformin — but at the cost of glucose-monitoring complexity

The practical issue is not that the combination is dangerous in absolute terms. It is that adding Giloy without dose adjustment of metformin destabilises previously controlled glucose. Many Indian diabetics add Giloy juice or tablets without informing their endocrinologist, then present with confusing glucose readings that do not match their established medication response.

Safer approach: If you are on metformin and want to try Giloy, inform your treating doctor, do daily home fasting glucose checks for the first 4 weeks of Giloy use, and be prepared for your doctor to consider lowering your metformin dose if your fasting glucose consistently drops below 90 mg/dL.

For a deeper picture of diabetes monitoring, see our guide to HbA1c testing in India and the diabetes treatment pillar guide.

Sulfonylureas (Glimepiride, Glibenclamide)

Sulfonylureas stimulate pancreatic insulin secretion. Adding Giloy to a sulfonylurea increases hypoglycemia risk more than adding it to metformin, because the underlying mechanism (insulin secretion) is already pushing glucose downward harder.

Indian endocrinology forum reports describe symptomatic hypoglycemia — fasting glucose 60–70 mg/dL with sweating, tremor, and dizziness — in elderly patients on glimepiride who added Giloy juice on family advice.

Practical rule: Avoid combining Giloy with sulfonylureas in the elderly, in patients with reduced kidney function, or in patients with hypoglycemia unawareness. If younger and otherwise healthy, monitor glucose carefully and consider a sulfonylurea dose reduction proactively.

DPP-4 Inhibitors (Sitagliptin, Vildagliptin, Linagliptin)

DPP-4 inhibitors carry low intrinsic hypoglycemia risk, so adding Giloy to a DPP-4 inhibitor is generally safer than adding it to a sulfonylurea. However, in patients on combination therapy (DPP-4 inhibitor + sulfonylurea or DPP-4 inhibitor + metformin), the cumulative effect with Giloy still warrants monitoring.

SGLT-2 Inhibitors (Empagliflozin, Dapagliflozin)

SGLT-2 inhibitors lower glucose through urinary glucose excretion and have low hypoglycemia risk in monotherapy. The interaction with Giloy is minimal. However, SGLT-2 inhibitors increase risk of urinary tract infections and dehydration — Giloy users on these drugs should maintain adequate water intake.

Insulin

Insulin therapy combined with Giloy carries the highest hypoglycemia risk. Indian Type 1 diabetics, late-stage Type 2 diabetics on insulin, and gestational diabetics on insulin should not add Giloy without endocrinologist supervision and likely insulin dose adjustment.

For Type 1 diabetics: Giloy’s effect adds approximately 5–15% to insulin sensitivity. Without proportional insulin reduction, severe hypoglycemia is likely.

For more on insulin glargine specifically (Lantus, Glaritus, Basalog), the most common basal insulin in Indian retail, see our insulin glargine deep dive.

GLP-1 Receptor Agonists (Semaglutide, Liraglutide, Orforglipron)

The newer GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy) and orforglipron — have low intrinsic hypoglycemia risk in monotherapy but carry GI side effects (nausea, vomiting, delayed gastric emptying). Adding Giloy may compound GI side effects, particularly in the first weeks of GLP-1 initiation. Otherwise, the combination is not particularly risky.

Anticoagulants and Antiplatelets: The Bleeding Risk

Patients on blood thinners are the second highest-risk group for Giloy interactions.

Warfarin and Acenocoumarol

Warfarin’s effect is measured by INR (International Normalized Ratio), maintained in a therapeutic range of typically 2.0–3.0 for most indications, or 2.5–3.5 for mechanical heart valves.

Adding Giloy can:

• Mildly increase INR through additive antiplatelet effect
• Destabilise previously stable INR readings
• Increase risk of bleeding episodes

The practical consequence is not usually a life-threatening bleed — it is INR variability. Patients on stable warfarin who add Giloy often find their INR pattern becomes erratic, requiring more frequent monitoring and dose adjustments.

Safer approach: Avoid Giloy if on warfarin unless you have a specific clinical reason to take it and your cardiologist agrees. If you do take it, double your INR monitoring frequency during the first 4 weeks.

DOACs (Direct Oral Anticoagulants — Dabigatran, Apixaban, Rivaroxaban)

Newer DOACs are commonly used in India for atrial fibrillation and DVT prevention. The interaction data with Giloy is less mature than with warfarin, but the same theoretical concern applies — additive bleeding risk through antiplatelet activity.

Without a clinical reason to take Giloy, patients on DOACs should avoid it.

Antiplatelets (Aspirin, Clopidogrel, Ticagrelor, Prasugrel)

Patients post-cardiac stent, post-heart bypass surgery, or post-stroke are routinely on dual antiplatelet therapy (DAPT) — usually aspirin plus clopidogrel for 6–12 months after the procedure, then aspirin lifelong.

Adding Giloy to DAPT increases bleeding risk meaningfully. Patients on DAPT should avoid Giloy entirely until their cardiologist confirms it is safe.

Aspirin (Low-Dose, Cardioprotective)

Many Indians over 40 take low-dose aspirin (75–150 mg/day) for cardiovascular risk reduction. Adding Giloy increases bleeding risk, though typically not dramatically. The main practical risk is increased gastric mucosal stress combined with aspirin’s gastric irritation.

Safer approach: Patients on cardioprotective aspirin can probably take short courses of Giloy (under 4 weeks) without dramatic bleeding risk. Avoid the combination if there is any history of GI bleeding, peptic ulcer, or H. pylori infection.

Thyroid Medications: The Autoimmune Flare Risk

This is the interaction category most relevant for Indian women, given the high prevalence of Hashimoto’s thyroiditis.

Levothyroxine for Autoimmune Hypothyroidism (Hashimoto’s)

Approximately 78.8% of hypothyroidism in Indian adults is caused by Hashimoto’s thyroiditis — an autoimmune disease where the immune system attacks the thyroid gland. Patients are typically on levothyroxine (Thyronorm, Eltroxin) for life.

Giloy’s immunostimulant effect can paradoxically flare the autoimmune attack:

• Anti-TPO antibody titres may rise
• TSH may destabilise from previously normalised values
• Symptoms — fatigue, hair loss, weight changes, mood instability — may return despite continued levothyroxine adherence

Indian Ayurveda hospital case reports document Hashimoto’s relapse in patients on previously stable levothyroxine who added Giloy plus ashwagandha as an “immunity booster” or thyroid-supporting regimen.

Safer approach: Patients on levothyroxine for Hashimoto’s should avoid Giloy. If they want to try Ayurvedic adjunct therapy, options like Kanchanar Guggulu have a longer Indian Ayurvedic track record for thyroid-supportive use, though even these warrant endocrinologist supervision. For the full thyroid picture, see our thyroid problems in India pillar guide.

Levothyroxine for Non-Autoimmune Hypothyroidism

For the smaller fraction of Indian hypothyroidism caused by non-autoimmune mechanisms (post-thyroidectomy, post-radioactive iodine, iodine deficiency), Giloy’s autoimmune flare risk does not apply. The remaining concern is whether Giloy alters thyroid hormone metabolism — some preclinical data suggests mild thyroid-stimulating activity, which could compound levothyroxine’s effect.

Patients in this category can probably take short Giloy courses with thyroid panel monitoring at 4 weeks.

Antithyroid Drugs (Methimazole, Carbimazole, Propylthiouracil)

Patients on antithyroid drugs for hyperthyroidism or Graves’ disease are usually treating an autoimmune condition. Giloy’s immunostimulant effect can flare the underlying autoimmunity, potentially worsening Graves’ disease activity. Avoid Giloy in this population.

Immunosuppressants: The Transplant Rejection Risk

Patients on immunosuppressant drugs — for organ transplant, autoimmune disease, or cancer treatment — are the single highest-risk group for Giloy interactions.

Tacrolimus and Cyclosporine (Transplant Patients)

Solid organ transplant recipients depend on tacrolimus or cyclosporine to prevent rejection. The therapeutic window for these drugs is narrow — too little allows rejection, too much causes nephrotoxicity and other adverse effects.

Adding Giloy:

• Stimulates the immune system, directly opposing the immunosuppressant
• May alter the metabolism of tacrolimus and cyclosporine through hepatic enzyme effects
• Adds hepatotoxic load to organs already monitoring drug-induced toxicity

The combined risk is acute organ rejection. Transplant patients should treat Giloy as a “do not use” medication regardless of any traditional health claims. Patients post-liver transplant, post-kidney transplant, or post-heart transplant are particularly at risk.

Methotrexate (Rheumatoid Arthritis, Psoriasis, Some Cancers)

Methotrexate is widely used in India for rheumatoid arthritis, psoriasis, and some leukaemias. It works partly through immunosuppression and partly through anti-folate metabolism.

Adding Giloy to methotrexate:

• Reduces methotrexate’s immunosuppressive efficacy through opposition
• Increases hepatic load (both drugs have hepatic involvement)
• May flare the underlying autoimmune disease through Giloy’s immunostimulant action

Indian rheumatology case reports describe paradoxical worsening of rheumatoid arthritis pain after Giloy addition. Avoid the combination.

Biologic DMARDs (Adalimumab, Etanercept, Infliximab, Rituximab)

Biologic DMARDs target specific immune pathways — TNF-α, IL-6, CD20, etc. Giloy’s broad immunostimulant action partially opposes these targeted therapies, potentially reducing efficacy.

Patients on biologics for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, or other autoimmune conditions should avoid Giloy.

Mycophenolate (Cellcept), Azathioprine (Imuran)

Both are used in transplant maintenance and autoimmune disease treatment. The opposition logic applies — Giloy stimulates what these drugs suppress. Avoid.

Corticosteroids (Prednisolone, Dexamethasone)

Patients on chronic oral corticosteroids — for autoimmune disease, COPD, or other inflammatory conditions — are immunosuppressed. Giloy partially opposes the steroid effect on the immune system. The opposition is less clinically dramatic than with calcineurin inhibitors but is still relevant.

Short-course steroid use (such as a 1-week prednisolone burst for asthma exacerbation) overlapping with short-course Giloy is generally not problematic. Chronic combined use is.

NSAIDs and Hepatotoxic Drug Combinations

NSAIDs (Diclofenac, Ibuprofen, Naproxen, Aceclofenac)

NSAIDs and Giloy combine to produce two main issues:

1. Possible reduced NSAID effect. Some preclinical evidence suggests Giloy modulates cyclooxygenase pathways, potentially reducing NSAID effectiveness. Indian rheumatology case reports note paradoxical worsening of inflammatory joint pain when Giloy is added to existing diclofenac or ibuprofen.
2. Combined GI stress. Both NSAIDs and Giloy can stress the gastric mucosa, particularly on an empty stomach. Combined use may increase gastritis risk.

NSAIDs also stress the kidneys; while Giloy’s renal effects are less documented than its hepatic effects, the combined load is best minimised in patients with any kidney function compromise.

Paracetamol (Acetaminophen)

Paracetamol (Dolo 650) is the most widely used over-the-counter analgesic in India. Combined short-course use with Giloy for acute fever is generally tolerated. Combined daily long-term use stacks hepatic load — both drugs have hepatic involvement, and the cumulative stress can unmask liver injury in susceptible individuals.

Avoid the combination if you regularly drink alcohol, have any pre-existing liver disease, or take other hepatotoxic medications.

Statins (Atorvastatin, Rosuvastatin, Simvastatin)

Statins have documented hepatic and muscle side effects. Adding Giloy increases the cumulative hepatic load. For most patients on statins, short-course Giloy use is probably tolerated, but baseline and 4-week LFT monitoring is sensible.

Anti-Tubercular Drugs (Isoniazid, Rifampicin, Pyrazinamide, Ethambutol)

Anti-TB drugs are among the most hepatotoxic of all medications in routine Indian clinical use. Patients on intensive-phase or continuation-phase TB therapy should not take Giloy. The combined hepatic load risks acute drug-induced liver injury, which is already a recognised complication of TB therapy alone.

Other Hepatotoxic Drugs

• Valproic acid (epilepsy)
• Amiodarone (cardiac arrhythmia)
• Methotrexate (already discussed under immunosuppressants)
• Nitrofurantoin (UTI)
• Erythromycin (antibiotic)

The same logic applies — combined hepatic stress increases the likelihood of unmasking injury in susceptible individuals.

Psychiatric Medications

The interaction data here is thin compared with other classes, but several theoretical concerns warrant mention.

SSRIs and SNRIs (Escitalopram, Sertraline, Fluoxetine, Venlafaxine, Duloxetine)

For escitalopram (Nexito, Cipralex) and related SSRIs, there is no well-documented dangerous interaction with Giloy. Theoretical concerns include serotonergic effects from some Giloy alkaloids and immunomodulatory effects on the immune-mood axis (relevant in depression with autoimmune comorbidity).

Practically, short-course Giloy with established SSRI therapy is probably safe, but inform your psychiatrist.

Benzodiazepines (Alprazolam, Clonazepam, Diazepam, Lorazepam)

Limited interaction data. Benzodiazepines work through GABAergic pathways; ashwagandha is known to interact significantly through this mechanism. Giloy’s GABAergic activity is less well characterised. Without clear data, monitor for sedation or anxiety symptoms when adding Giloy to benzodiazepine therapy.

Lithium, Antipsychotics, Mood Stabilisers

For lithium specifically, the renal monitoring requirement of lithium therapy combined with any new herbal supplement warrants caution. For atypical antipsychotics (olanzapine, quetiapine, risperidone), the metabolic side effects (weight gain, blood sugar elevation) may be slightly offset by Giloy’s glucose-lowering effect — but this is not a therapeutic benefit, just a confounder for monitoring.

Cancer Treatment Interactions

This is one of the most under-discussed Giloy interaction categories.

Conventional Chemotherapy

Many cytotoxic chemotherapy drugs work partly through immune suppression (which is sometimes therapeutic in haematological cancers) and partly through direct cytotoxic action. Giloy’s immune-stimulant effect can interfere with chemotherapy in unpredictable ways.

Additionally, many chemotherapy drugs are hepatotoxic. Adding Giloy increases cumulative liver stress in patients whose liver is already monitoring multiple drugs.

Targeted Therapy and Hormonal Therapy

Drugs like trastuzumab (Herceptin), tamoxifen, aromatase inhibitors, and tyrosine kinase inhibitors have variable interaction profiles. For most, the data on Giloy interaction is sparse. The default safe approach is to avoid Giloy during active cancer treatment unless your medical oncologist specifically approves it.

Immunotherapy (Checkpoint Inhibitors)

Pembrolizumab, nivolumab, ipilimumab, and other checkpoint inhibitors work by unblocking the immune system to attack tumours. Combining these with Giloy’s broad immunostimulant action produces unpredictable effects:

• Potentially amplified immune-related adverse events (autoimmune side effects of checkpoint inhibitors)
• Potential interference with the precise immune modulation these drugs are designed to achieve

Patients on checkpoint inhibitor immunotherapy should not take Giloy. Inform your oncology team about any prior herbal supplement use as well.

CDK4/6 Inhibitors and Other Newer Cancer Drugs

For agents like vepdegestrant and other newer oncology drugs, the interaction database is essentially empty for Giloy. Default to avoidance during active treatment.

Antibiotics and Antivirals

Common Antibiotics (Azithromycin, Amoxicillin, Doxycycline)

For short-course antibiotic treatment overlapping with Giloy, the interaction concern is minimal. The main caveat is that combining multiple immunoactive treatments (Giloy + antibiotics + perhaps other supplements) can produce confusing symptom patterns that complicate clinical assessment.

Fluoroquinolones (Ciprofloxacin, Levofloxacin)

Fluoroquinolones have documented hepatic and tendon side effects. Combining with Giloy adds hepatic stress without clear benefit.

Hydroxychloroquine

For patients on hydroxychloroquine for rheumatological conditions, the immunostimulant opposition logic applies — Giloy partially counteracts hydroxychloroquine’s immunomodulatory effect.

Hormonal Medications

Oral Contraceptives

No well-documented dangerous interaction. Theoretical immune effects on hormone receptor sensitivity exist but are not clinically significant in most users.

Hormone Replacement Therapy (HRT)

Limited data. Avoid in patients with hormone-sensitive cancers (breast, endometrial).

Anti-Diabetic Hormone Therapies

GLP-1 agonists discussed above under diabetes medications.

The COVID-Era Stacking Disaster

A specific Indian clinical pattern deserves its own section. During India’s COVID-19 waves of 2020–2022, a popular self-medication regimen included:

• Giloy (juice or tablets)
• Ashwagandha (capsules or churna)
• Tulsi (juice or kadha)
• Sometimes Mulethi, Kalmegh, or Kabasura Kudineer
• Often combined with vitamin C, vitamin D, and zinc supplements
• Frequently overlapping with paracetamol for fever and azithromycin for prophylaxis

This stack combined multiple immunostimulant herbs with multiple hepatic stressors over weeks of continuous use. The hepatology case literature documents this period as the highest-yield era for Indian herb-induced liver injury, autoimmune flares, and complex polypharmacy presentations.

If you are still on a daily “immunity kit” combining multiple Ayurvedic herbs, the single most important behavioural change is to stop combining them. Pick one herb for one indication, use it for a defined course (4–6 weeks maximum), then stop. The stack is more dangerous than any single component.

Practical Rules for Combining Giloy with Prescription Medication

Distilled from the drug-class breakdown above:

1. Tell your treating doctor. Even if you assume “they don’t know about herbs,” inform them before starting. The disclosure itself protects you in the rare event of an adverse interaction.
2. One herb at a time. Do not stack Giloy with ashwagandha, tulsi, or other Ayurvedic immunomodulators.
3. Short courses. 4–6 weeks maximum continuous use, followed by 2–4 weeks off.
4. Baseline bloodwork. Before any course longer than 4 weeks, baseline LFT, thyroid panel if relevant, and HbA1c if diabetic. See our CBC test guide for context on routine panels.
5. Monitor while on therapy. Home glucose for diabetics, repeat LFT at 4 weeks, watch for jaundice / dark urine / unusual fatigue.
6. Avoid in high-risk groups. Transplant patients, autoimmune disease patients in remission, cancer patients on active treatment, pregnant women, patients with liver disease.
7. Be especially careful with old medications. Patients on multiple chronic medications (typically elderly Indians with diabetes + hypertension + cardiac history) are at highest risk of complex interactions.
8. Stop and reassess. If symptoms develop — confusing glucose readings, unusual fatigue, mood instability, GI upset — stop the Giloy and see your doctor. Do not push through.

Cross-Cluster Reading

For the full picture of safe Giloy use, this drug-interaction guide is part of a cluster with:

• The Giloy medicine pillar — full dosing, brand comparison, and uses guide at Giloy (Guduchi) deep dive
• The 2021 Mumbai hepatitis cases — full investigation at Mumbai Giloy hepatitis cases
• Brand purity and lab data — synthesis of Indian phytochemistry studies at Giloy brand purity analysis
• Visual identification of fake Giloy — at spotting genuine vs adulterated Giloy
• Authentic satva process — at Giloy satva traditional process

For the parallel safety picture in Ashwagandha, including its 471 documented drug interactions, see the Ashwagandha medicine deep dive.

Frequently Asked Questions

Can I take Giloy if I have controlled hypertension on telmisartan or amlodipine?

Probably yes, with caution. Giloy has minimal documented direct interaction with common Indian antihypertensives (telmisartan, amlodipine, losartan, ramipril). The main concern is the combined effect with antiplatelet medication often prescribed alongside (low-dose aspirin in patients over 40 with cardiac risk factors). Monitor BP during the first 2 weeks of Giloy use — mild additional BP lowering is possible.

Does Giloy interact with sleep medications like zolpidem or melatonin?

Limited interaction data. Theoretical concern exists for GABAergic synergy producing excess sedation, but the clinical evidence is sparse. If you are on chronic zolpidem (Stilnoct) or take melatonin nightly, start Giloy at half the typical dose for the first week and monitor for excessive morning grogginess.

Can Giloy be combined with vitamin and mineral supplements?

Generally yes. No significant interactions with vitamin D, vitamin B complex, iron, calcium, magnesium, zinc, or vitamin C are documented. The main practical issue is “supplement stacking” — taking too many simultaneously creates monitoring complexity. Pick the supplements you genuinely need based on bloodwork, not on aspirational claims.

Is short-course Giloy safe during a viral fever even if I take other medications?

For most adults on common medications, a 5–7 day course of Giloy during acute viral fever, alongside paracetamol and adequate hydration, is reasonable. Exceptions: patients on warfarin, immunosuppressants, methotrexate, biological DMARDs, active chemotherapy, or with documented liver disease should avoid even short-course use without medical clearance.

How long after stopping Giloy do drug interaction effects subside?

Most Giloy interactions resolve within 1–2 weeks of stopping the herb. The exception is the autoimmune flare risk in Hashimoto’s or other autoimmune conditions — once a flare is triggered, resolution may take several months and may require corticosteroid intervention. This is one reason to avoid Giloy entirely in patients with autoimmune disease rather than try short courses.

Are there safer Indian herbs without these drug interaction concerns?

Some Indian herbs have lower documented interaction load than Giloy or Ashwagandha. Triphala (a combination of three fruits) has well-documented digestive use with relatively few major drug interactions. Brahmi (Bacopa monnieri) is widely used for cognitive support with a modest interaction profile. Amla (Indian gooseberry) is generally well tolerated in food doses. However, “fewer documented interactions” sometimes means “less studied” rather than “actually safer” — always disclose any herbal supplement use to your treating physician.

Should I stop Giloy before a planned surgery?

Yes. Stop Giloy at least 2 weeks before any planned surgical procedure. The antiplatelet effect can complicate intraoperative bleeding, the immunomodulatory effect can alter surgical infection risk, and the hepatic and glycemic effects can complicate anaesthesia management. Inform your surgical team about Giloy and any other herbal supplement use during the pre-anaesthetic consultation.

Can I take Giloy while breastfeeding?

No. Avoid Giloy during breastfeeding. No human data exists on whether Giloy compounds pass into breastmilk. The immunomodulatory and bitter alkaloid content could plausibly affect an infant’s developing immune system or digestive tract. For nursing-relevant herbal questions, prefer consultation with a paediatrician and lactation consultant rather than e-commerce product claims.

Does Giloy interfere with vaccines?

Theoretically possible but not well documented. Giloy’s immunostimulant effect could theoretically alter vaccine response — either reducing it or amplifying side effects. For routine adult vaccines (annual flu, COVID boosters, tetanus boosters), the practical effect is probably negligible. For travel vaccines or specialised immunisation schedules (such as hepatitis B series for healthcare workers), consider not taking Giloy in the week before and 2 weeks after vaccination.

What is the single highest-risk drug to combine with Giloy in an Indian adult?

For chronic combination: tacrolimus or cyclosporine in transplant recipients. The acute rejection risk is potentially catastrophic.

For common combination missed by many Indians: warfarin in elderly patients with atrial fibrillation. The bleeding risk is real and INR destabilisation is common.

For widespread combination causing the most preventable harm: insulin or sulfonylureas in elderly diabetics who add Giloy on family advice without informing their endocrinologist. The resulting hypoglycemia episodes are common and frequently lead to emergency presentations.

---

This article is for informational purposes only and does not constitute medical advice. Drug interaction information is synthesised from published pharmacology literature, Indian clinical case reports, and pharmacological plausibility. Specific interactions for individual patients depend on the full medication list, comorbidities, and individual response. Always consult your treating physician — endocrinologist, cardiologist, hepatologist, rheumatologist, oncologist, or psychiatrist as relevant — before starting Giloy or any herbal supplement alongside prescription medication. Disclose all herbal supplement use during routine medical visits, particularly before any planned procedure or dose adjustment of prescription medications.